<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112175</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-026</org_study_id>
    <nct_id>NCT02112175</nct_id>
  </id_info>
  <brief_title>Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM</brief_title>
  <acronym>ARUMM</acronym>
  <official_title>Phase 3B, Randomized Trial of Lenalidomide Versus Placebo Maintenance Therapy Following Melphalan Prednisone Bortezomib Induction Therapy in Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Lanalidomide versus
      Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly
      diagnosed multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) defined as the time from randomization to the first objective tumor progression according to International Myeloma Working Group (IMWG) criteria or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response Rate (ORR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR (complete response [CR], very good partial response [VGPR] and partial response [PR]): during the maintenance phase, according to IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival 2 (PFS2)</measure>
    <time_frame>Approximately 6 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS2: Time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 6 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS defined as the time from the date of randomization to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Approximately 6 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Approximately 351 patients with AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>QoL: Changes from baseline in overall scores and sub-scores using the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire for palliative care for Subjects with Cancer (EORTC QLQ-C15-PAL) Module, and the descriptive system of the EuroQoL 5-dimensions (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytomorphology</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of the qualitative description of bone marrow and peripheral blood morphology at baseline with the development of MDS/AML cases reported as SPMs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of Cumulative Illness Rating Scale (Geriatric version) of subjects at baseline to clinical outcomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Arm B: placebo orally from Days 1 to 21; given in 28-day cycles for up to disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Lenalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following inclusion criteria to be eligible for
             enrollment into the study:

        Related to initial diagnosis and prior Melphalan Prednisone Velcade (MPV) induction
        therapy

          1. Previously untreated and symptomatic multiple myeloma.

          2. All 3 criteria (Durie, 2003) and at least one of the Creatinine Renal insufficiency
             Anemia lytic Bone lesions or osteoporosis criteria must be met.

          3. Measurable disease by protein electrophoresis analyses.

          4. All subjects must be treated with a minimum of 6 and a maximum of 9 cycles of MPV
             induction regimen, and must have achieved at least Partial Response as best overall
             response and maintained at Melphalan Predinisone Velcade discontinuation. If a
             subject achieves Complete Response prior to at least 6 cycles, the subject will be
             eligible, but a minimum of 6 cycles must be administered otherwise.

          5. Subjects must not have received any prior anti-myeloma chemotherapy or any
             investigational agent except 6-9 cycles of induction therapy with Melphalan
             Predinisone Velcade.

          6. Subjects must have cytogenetic (17 p deletion, and 4;14 translocation), β-2
             microglobulin and serum albumin (International Staging System) results from their
             initial diagnosis available at the time of  screening.

             Related to the subject

          7. Must understand and voluntarily sign the informed consent document prior to the
             conduct of any study related assessments/procedures,

          8. Age ≥ 65 years: if &lt; 65 years of age, the subject must be non eligible for stem cell
             transplantation,

          9. Eastern Cooperative Oncology Group performance status score ≤ 2,

         10. Able to adhere to the study visit schedules and other protocol requirements,

         11. Females of Childbearing Potential must:

               1. Have two negative pregnancy tests as verified by the study doctor prior to
                  starting study therapy. She must agree to ongoing pregnancy testing during the
                  course of the study, and after the end of study therapy. This applies even if
                  the subject practices true abstinence2 from heterosexual contact.

               2. Either commit to true abstinence from heterosexual contact (which must be
                  reviewed on a monthly basis) or agree to use, and be able to comply with,
                  effective contraception without interruption, 28 days prior to starting
                  Investigational Product, during the study therapy (including dose
                  interruptions), and for 28 days after discontinuation of study therapy.

         12. Male Subjects must:

               1. Practice true abstinence or agree to use a condom during sexual contact with a
                  pregnant female or a female or childbearing potential while participating in the
                  study, during dose interruptions and for at least 28 days following
                  Investigational Product discontinuation, even if he has undergone a successful
                  vasectomy.

               2. Agree to not donate semen during Investigational Product therapy and for 28 days
                  after end of study therapy.

         13. All subjects must:

               1. Have an understanding that the study medication could have a potential
                  teratogenic risk.

               2. Agree to abstain from donating blood while taking Investigational Product
                  therapy and following discontinuation of Investigational Product therapy.

               3. Agree not to share study medication with another person.

               4. All female of childbearing potential and male subjects must be counseled about
                  pregnancy precautions and risks of fetal exposure.

        Exclusion Criteria:

          -  The presence of any of the following will exclude the subject from the study
             enrollment:

               1. Previous treatment with anti-myeloma therapy other than the required 6-9 cycles
                  of Melphalan Prednisone Velcade induction therapy (does not include local
                  radiotherapy, bisphosphonates, or a single short course of steroid [ie, less
                  than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a
                  short course of steroid treatment must not have been given within 14 days of
                  randomization]).

               2. Subjects who didn't achieve Partial Response or better after getting at least 6
                  cycles of Melphalan Predinisone Velcade and at the end of Melphalan Prednisone
                  Velcade whatever the overall response are not eligible.

               3. Prior therapy with immunomodulating or immunosuppressive agents, or epigenetic
                  or desoxyribonucleic acid modulating agents. Subjects who received
                  investigational agents are also excluded.

               4. Any significant medical condition, laboratory abnormality, or psychiatric
                  illness that would prevent the subject from participating in the study.

               5. Any condition including the presence of laboratory abnormalities, which places
                  the subject at unacceptable risk if he/she were to participate in the study

               6. Pregnant or lactating females.

               7. Any of the following laboratory abnormalities:

                  Absolute neutrophil count &lt; 1,000/L (1.0 x 10*9/L) Untransfused platelet count &lt;
                  50,000 cells/L (50 x 10*9/L) Serum glutamic oxaloacetic transaminase/alanine
                  aminotransferase or serum glutamic pyruvic transaminase/alanine aminotransferase
                  &gt; 3.0 x upper limit of normal Serum bilirubin levels &gt; 1.5 x upper limit of
                  normal

               8. Renal insufficiency (creatinine clearance &lt; 30 mL/min by Cockroft-Gault method)
                  or actual creatinine clearance result, or renal failure requiring hemodialysis
                  or peritonela dialysis.

               9. Prior history of malignancies including skin cancer, other than multiple
                  myeloma.

              10. Prior history of deep venous thrombosis or pulmonary embolus within 3 years of
                  randomization.

              11. Subjects who are unable or unwilling to undergo anti-thrombotic therapy.

              12. Peripheral neuropathy of &gt; Grade 2 severity according to the National Cancer
                  Institute Common Terminology Criteria for Adverse Events Version 4.0.

              13. Known Human Immunodeficiency Virus positivity or active infectious hepatitis,
                  type A, B, or C.

              14. Primary amyloidosis (immunoglobulin light chain) and myeloma complicated by
                  amyloidosis.

              15. Prior allogeneic or autologous stem cell transplantation.

              16. Significant active cardiac disease within the previous 6 months including:

                  New York Heart Association class II-IV congestive heart failure Unstable angina
                  or angina requiring surgical or medical intervention Myocardial infarction

              17. Any condition that confounds the ability to interpret data from the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU UCL Montgodinne-Dinant</name>
      <address>
        <city>Yvoir</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de Fleyriat</name>
      <address>
        <city>Bourg en Bresse Cedex</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côté de Nacre</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental site de la Roche-sur-Yon</name>
      <address>
        <city>La Roche sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU-Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Nantes Hotel-Dieu</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Brieuc</name>
      <address>
        <city>St-Brieuc Cedex 1</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Strasbourg Oncologie Liberale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan, CHRU Toulouse</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpitaux Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación para la Investigación Biomedica del Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital C.U.Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Fé</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón La Floresta</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>MPV</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Velcade</keyword>
  <keyword>Placebo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
